Anesthesia for Transcatheter Aortic Valve Replacement (TAVR) and Other Catheter-Based Intracardiac Procedures

  • Ratna VadlamudiEmail author


Aortic valve disease, particularly aortic stenosis (AS), is a very common form of valvular heart disease in developed countries (Horne et al., Am Heart J 168:414–423, 2014).

Aortic valve replacement (AVR) is indicated in symptomatic patients. However, there exist patient populations where surgical AVR (SAVR) is considered to have prohibitive risk, particularly as the population ages and significant co-morbid conditions develop. Medical management of these patients can reduce symptoms and improve quality of life to some extent but gold standard therapy is replacement of the aortic valve (Horne et al., Am Heart J 168:414–423, 2014).

Transcatheter aortic valve replacement (TAVR) was developed as an alternate method for treating severe AS in these high-risk patient populations.

Due in part to the success of TAVR, innovation in the field has developed other percutaneous valve therapies.


Anesthesia for transcatheter aortic valve replacement (TAVR) Anesthesia for transcatheter mitral valve repair or replacement MitraClip Anesthesia for transcatheter tricuspid valve repair or replacement Anesthesia for transcatheter pulmonic valve replacement Valvular heart disease 


  1. 1.
    Grover FL, Vemulapalli S, Carroll JD, et al. 2016 annual report of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. J Am Coll Cardiol. 2017;69(10):1215–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Decision memo for transcatheter aortic valve replacement (TAVR) (CAG-00430N).
  3. 3.
    Babaliaros V, Devireddy C, Lerakis S, et al. Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach). J Am Coll Cardiol Intv. 2014;7:898–904.CrossRefGoogle Scholar
  4. 4.
    Tsai MT, Tang GHL, Cohen GN. Year in review: transcatheter aortic valve replacement. Curr Opin Cardiol. 2016;31:139–47.CrossRefPubMedGoogle Scholar
  5. 5.
    Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomized controlled trial. Lancet. 2015;385(9986):2477–84.CrossRefGoogle Scholar
  6. 6.
    Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370(19):1790–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Horne A, Reineck E, Hasan RK, et al. Transcatheter aortic valve replacement: historical perspectives, current evidence, and future directions. Am Heart J. 2014;168:414–23.CrossRefPubMedGoogle Scholar
  8. 8.
    Reardon MJ, Adams DH, Kleiman NS, et al. 2-year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement. JACC. 2015;66(2):113–21.CrossRefPubMedGoogle Scholar
  9. 9.
    Hahn RT. Guidance of transcatheter aortic valve replacement by echocardiography. Curr Cardiol Rep. 2014;16(1):442.CrossRefPubMedGoogle Scholar
  10. 10.
    Gössl M, Farivar RS, Bae R, et al. Current status of catheter-based treatment of mitral valve regurgitation. Curr Cardiol Rep. 2017;19(5):38.CrossRefPubMedGoogle Scholar
  11. 11.
    Bouleti C, Juliard JM, Himbert D, et al. Tricuspid valve and percutaneous approach: no longer the forgotten valve! Arch Cardiovasc Dis. 2016;109:55–66.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Emory University School of Medicine, Emory University HospitalAtlantaUSA

Personalised recommendations